Motexafin gadolinium: a promising radiation sensitizer in brain metastasis.

Abstract

INTRODUCTION:

Motexafin gadolinium is a radiation sensitizer that is in the class of drugs known as texaphyrins. Though this drug is currently not FDA approved in the management of brain tumors, several prospective studies have been done showing promise with this agent, which this review highlights.

AREAS COVERED:

This paper provides a clinical context by reviewing the background of radiosensitizers, followed by a review of the preclinical discovery of motexafin gadolinium and its clinical testing. We also highlight its most promising applications and comment on the reasons for the observed clinical outcomes.

EXPERT OPINION:

Motexafin gadolinium is a novel radiosensitizer with clearly documented efficacy, particularly in patients with brain metastases. If this agent had been tested upfront in patients diagnosed with brain metastases from NSCLC who had not been delayed by the administration of systemic chemotherapy, it may have become part of the standard of care in this setting. Continued investigations using this agent are under way and remain promising.

• Authors: Sayana Rachel Thomas, Deepak Khuntia
• Journal: Expert opinion on drug discovery (Expert Opin Drug Discov) Vol. 6 Issue 2 Pg. 195-203 (Feb 2011) ISSN: 1746-045X [Electronic] England
• PMID: 22647136 (Publication Type: Journal Article)